Copyright © Inderes 2011 - present. All rights reserved.

Scandion Oncology

0.073

 

SEK

 

-3.97 %

SCOL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Be the first to follow this company
-3.97%
-42.91%
-56.33%
-80.72%
-94.02%
-86.26%
-98.38%
-96.97%
-96.92%
scandiononcology.com/investors-media

Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.

Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SCOL
Daily low / high price
0.07 / 0.073 SEK
Market cap
16.81M SEK
Turnover
43.07K SEK
Volume
606K

Latest videos

Scandion Oncology, Audiocast with teleconference, Q3'24
2024-11-11
Scandion Oncology, Audiocast with teleconference, Q2'24
2024-08-29
Scandion Oncology, Audiocast with teleconference, Q1'24
2024-05-22

Financial calendar

Annual report
2025-02-27
General meeting
2025-04-29
Interim report
2025-05-22
Interim report
2025-08-28
Interim report
2025-11-11
Login in to make your own estimates and see other investors estimates.
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account